Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,771 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I/II study of GLIF combination chemotherapy for taxane/platinum-refractory/resistant endometrial cancer (GOGO-EM2).
Tanaka Y, Ueda Y, Nakagawa S, Matsuzaki S, Kobayashi E, Shiki Y, Nishio Y, Takemura M, Yamamoto T, Sawada K, Tomimatsu T, Yoshino K, Kimura T. Tanaka Y, et al. Among authors: ueda y. Cancer Chemother Pharmacol. 2018 Oct;82(4):585-592. doi: 10.1007/s00280-018-3648-y. Epub 2018 Jul 20. Cancer Chemother Pharmacol. 2018. PMID: 30030584 Free PMC article. Clinical Trial.
Altered protein expression in endometrial carcinogenesis.
Yoshizaki T, Enomoto T, Nakashima R, Ueda Y, Kanao H, Yoshino K, Fukumoto M, Yoneda Y, Buzard GS, Murata Y. Yoshizaki T, et al. Among authors: ueda y. Cancer Lett. 2005 Aug 26;226(2):101-6. doi: 10.1016/j.canlet.2004.11.053. Epub 2005 Jan 21. Cancer Lett. 2005. PMID: 16039949
Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
Yamada Y, Tamura T, Yamamoto N, Shimoyama T, Ueda Y, Murakami H, Kusaba H, Kamiya Y, Saka H, Tanigawara Y, McGovren JP, Natsumeda Y. Yamada Y, et al. Among authors: ueda y. Cancer Chemother Pharmacol. 2006 Aug;58(2):173-82. doi: 10.1007/s00280-005-0149-6. Epub 2005 Nov 25. Cancer Chemother Pharmacol. 2006. PMID: 16308697 Clinical Trial.
Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin.
Ueno Y, Enomoto T, Otsuki Y, Sugita N, Nakashima R, Yoshino K, Kuragaki C, Ueda Y, Aki T, Ikegami H, Yamazaki M, Ito K, Nagamatsu M, Nishizaki T, Asada M, Kameda T, Wakimoto A, Mizutani T, Yamada T, Murata Y. Ueno Y, et al. Among authors: ueda y. Cancer Lett. 2006 Sep 28;241(2):289-300. doi: 10.1016/j.canlet.2005.10.035. Epub 2006 Feb 3. Cancer Lett. 2006. PMID: 16459017
Clonality analysis and human papillomavirus infection in squamous metaplasia and atypical immature metaplasia of uterine cervix: is atypical immature metaplasia a precursor to cervical intraepithelial neoplasia 3?
Miyatake T, Ueda Y, Yoshino K, Shroyer KR, Kanao H, Sun H, Nakashima R, Kimura T, Wakasa T, Enomoto T. Miyatake T, et al. Among authors: ueda y. Int J Gynecol Pathol. 2007 Apr;26(2):180-7. doi: 10.1097/01.pgp.0000235068.16054.39. Int J Gynecol Pathol. 2007. PMID: 17413987
Frequent inactivation of RUNX3 in endometrial carcinoma.
Yoshizaki T, Enomoto T, Fujita M, Ueda Y, Miyatake T, Fujiwara K, Miyake T, Kimura T, Yoshino K, Kimura T. Yoshizaki T, et al. Among authors: ueda y. Gynecol Oncol. 2008 Sep;110(3):439-44. doi: 10.1016/j.ygyno.2008.05.004. Epub 2008 Jun 24. Gynecol Oncol. 2008. PMID: 18572225
4,771 results